A recent study performed on mild to moderate AD patients showed that treatment with GM-CSF provided memory-enhancing benefits [45], and a clinical trial (NCT04902703) on AD patients for evaluating the safety and efficacy of GM-CSF (Sargramostim) is ongoing. The gene discussed is CSF2; the disease is Alzheimer disease.